India Dexamethasone Market to Witness Significant Growth During Forecast Period
Increasing number of cases and deaths caused due to COVID-19
is expected to drive the growth of India dexamethasone market
According
to TechSci Research report, “India Dexamethasone Market By Type (Injectables,
Capsules, Tablets, Solutions), By Route of Administration (Oral v/s
Intravenous), By Application (Asthma, Rheumatoid Arthritis, Skin Disorders,
Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By
End Users (Hospitals, Clinics, Pharmacy, Others), By Region, Forecast &
Opportunities, FY2026”, the India dexamethasone market
is expected to grow at an impressive rate during the forecast period on account
of the use for treating various diseases such as arthritis, skin conditions,
eye care, respiratory & breathing problems, among others. Additionally,
dexamethasone is a corticosteroid hormone which decreases body’s own defensive
response and reduces symptoms such as swelling, allergic reactions, among
others. This is an off-patent drug which is sold as a generic drug and also
under the brand name DexPak, which is cost effective and manufactured by
various big and small pharmaceutical companies in the country. Furthermore, the
use of drug in high risk patients of COVID-19 is further expected to spur the
market growth. However, side effects such as irritability, insomnia, muscle
weakness, fluid retention, mood swings, increased appetite, increased blood
sugar level, among others might hamper the market growth through FY2026. Also,
cytokine over storm while fighting the deadly coronavirus might further
restrict the market growth over the next few years.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on " India Dexamethasone
Market"
https://www.techsciresearch.com/report/india-dexamethasone-market/4935.html
The India dexamethasone market is segmented based on type, route of
administration, application, end users, company and region. Based on type, the market can be
categorized into injectables, capsules, tablets, and solutions. Here, the tablets
segment is expected to dominate the market since they are safe, inexpensive,
and safest form of oral medication. Additionally, they have a long shelf life,
durable, chewable and can be split. Also, they can accommodate high dose of
active ingredient. On the other hand, the capsule segment is expected to
witness significant growth in the market since these are tasteless, tamper
resistant and break down faster and easily. Further, they have a higher
bioavailability and make a large amount of drug enter the bloodstream. Based on route of administration, the
market can be split into oral and intravenous. Among these, the oral route is
expected to dominate the market on account of its ease, safety,
self-administration, prolonged absorption, among others. Additionally, the ease
of digestion, efficient patient compliance and ability to accommodate various
types of drugs further drive the segmental growth.
Cadila Healthcare Ltd., Wockhardt Ltd., Dwarkesh Pharmaceuticals Private
Limited, Schwitz Biotech, Lexine Technochem Private Limited, Mapro Lifescience,
Therawin Formulations, Shervotec Pharmaceuticals, Acichem Laboratories, Quality
Nexgen Pharmaceuticals Pvt Ltd and others are some of the leading players
operating in India dexamethasone market.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4935
Customers can also
request for 10% free customization on this report.
“India dexamethasone market is expected
to grow at a formidable rate during the forecast period on account of the
emergence of the drug as a potential option to treat chronic COVID-19 patients
and increasing the survival rate. India has a large number of pharmaceutical
companies that are producing the drug at a very affordable rate. However, an
increase in the price of API is expected by the drug manufacturers since more
than 75% of the API are exported from China but due to the current border
tensions with China and also halt in trading activities might lead to an
increase in the manufacturing costs during the forecast period. Moreover, the
drug has brought a ray of hope to the world for preventing deaths due to COVID-19
and if it gets the approval from FDA it will create lucrative opportunities for
the market growth. Also, it will be quite beneficial for Indian pharmaceutical
industry since India is one among the major producers of the drug.” said
Mr. Karan Chechi, Research Director with TechSci Research, a research based global
management consulting firm.
“India Dexamethasone Market By Type (Injectables,
Capsules, Tablets, Solutions), By Route of Administration (Oral v/s
Intravenous), By Application (Asthma, Rheumatoid Arthritis, Skin Disorders,
Covid-19, Ulcerative Colitis, Lupus, Allergic Disorders, Psoriasis, Others), By
End Users (Hospitals, Clinics, Pharmacy, Others), By Region, Forecast &
Opportunities, FY2026”,has evaluated the future growth potential of India dexamethasone
market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in India dexamethasone market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]